← Tra cứu cổ phiếu

iShareInvest Research

UPCOM · Quý 2/2026

DTP

Dược phẩm CPC1 Hà Nội

Analysis of business results & financial statements · Quý 2/2026

▼ Slightly negative

Trailing net profit reached 274.3bn, rose 21.1bn compared with the same period last year. Key positives came from higher gross profit, better other profit, and lower tax. Offsetting pressure came mainly from higher selling expenses and higher administrative expenses. Detailed impact is shown below:

See what is changing ↓
P/E
7.41x
P/B
1.95x
EPS
8,092
BVPS
30,796
ROE
24.0%
ROA
18.3%
Market price
60,000
16 Oct 2026

What Is Changing

On a TTM 2026Q2 basis, DTP is showing a few mildly negative signals versus the same period, though nothing alarming at current levels — profit is near a multi-period low. The point still to be proven is whether this is a short adjustment or the beginning of a weaker trend.

Profit bridge

Vs last year · TTM

  1. Gross profit
  2. Other profit
  3. Tax
  4. Selling expenses
  5. Administrative expenses
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 2/2026

MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue462.8412.4554.1417.3393.9329.5398.6309.9
LNST58.255.461.699.179.659.244.270.2
Net margin12.58%13.43%11.11%23.74%20.22%17.97%11.09%22.64%

Revenue

463bn

Net income

58bn

Net margin

12.58%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins narrowed but earnings quality remains clean — pressure is mainly operational.

Revenue Growth

▲

Is growth real and durable?

Trailing-12-month revenue grew 29.0% year on year — but the quarterly pace is slowing (+35% → +18%).

4 of the last 4 quarters grew year on year.

Revenue TTM
1,847bn
+29.0%
Latest quarter YoY
+18%
slowing

What is driving the margin?

▼

Net margin fell to 14.85%, losing 2.8pp. The main pressure comes from SG&A / Revenue rose 3.5pp and Gross margin fell 0.7pp (with additional support from Other profit / Revenue rose 0.4pp and Net financial result / Revenue rose 0.2pp).

The pressure comes from core operations — this is a concerning type of decline, not a one-off movement.

Net Margin
14.85%
−2.8pp
Gross Margin
51.37%
−0.7pp
SG&A / Revenue
34.74%
+3.5pp

TTM YoY · 2025Q2 -> 2026Q2

Cash Flow

▼

Is profit converting into cash?

With leverage safe, cash flow shows the self-funding capacity. Operating cash flow reached 367.7bn against investing cash flow of -261.9bn (annual cash-flow figures for 2025).

Post-investment cash flow was positive +105.8bn. Financing cash flow was negative +23.6bn.

CFO / net income was 1,09 lần.

After spending +280.3bn on fixed-asset investment, the business generated trailing free cash flow of +19.6bn.

Earnings Quality

▲

How much income is non-core?

About 100% of pre-tax profit comes from core operations.

Within that, net financial result at −0.0%, other profit at +0.2% of PBT.

Non-core / PBT
0.2%
low
Net financial / PBT
−0.0%
Other profit / PBT
0.2%
02

Is capital being used efficiently?

Capital efficiency is declining — check whether the drag is from margins or turnover.

Is capital being deployed efficiently?

▼▼

ROIC fell to 23.67%, losing 2.7pp. That translates to 23.67 in after-tax operating profit for every 100 units of operating capital. The main pressure came from NOPAT margin narrowed 3.1pp, outweighing the movement in capital turnover; while invested capital rose by 180bn.

Pressure came from the margin side — core operations are weakening, not just a temporary asset-management issue.

Working Capital Efficiency

▲▲

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 49.0 days versus the same period last year. The main moves came from DIO fell 43.4 days, DSO fell 12.0 days, and DPO fell 6.5 days.

Improvement comes mainly from faster inventory turnover — watch whether this trend persists in coming periods.

Cash conversion cycle remains stretched

CCC stands at 217.7 days, suggesting that working capital remains tied up for a relatively long operating cycle.

DuPont

What drives ROE?

Net margin 14.9% -2.8pp
Asset turnover 1.23x +0.10x
Financial leverage 1.31x -0.02x
ROE 24.0% -2.7pp

ROE fell from 26.7% to 24.0% — net margin weakened the most, though asset turnover still provided support.

03

Is financial risk significant?

Financial risk is low — leverage is safe, both CFO and FCF are positive.

Leverage & Liquidity

▲

Leverage looks fairly comfortable, with net debt / equity at 0.01x and interest coverage at 62.57x.

At present, short-term debt accounts for 45.1% of total debt, cash equals 87.7% of debt, and total debt stands at 128.0bn.

Net Debt / Equity
0.01x
+0.01x
Interest Coverage
62.57x
+13.67x
Cash / Debt
87.7%
−2.5pp
Short-term Debt / Total Debt
45.1%
−19.5pp

TTM YoY · 2025Q2 -> 2026Q2

Balance Sheet

●

The balance sheet shows capital-allocation efficiency slipping. Capital structure is conservative with low leverage — liabilities at 0.32x equity, net debt at 0.01x equity.

Inventory ended the period at 424.4bn, roughly 26.8% of total assets.

Over the last 12 months, working capital released 71.7bn of cash, mainly thanks to higher payables. Pressure from higher receivables and higher inventories only partly offset that benefit.

Research synthesis

What this reporting period is showing

The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is earnings conversion is confirmed, with CFO/NI at 1.09x. The main risk still sits in core profitability, with net margin down 2.8 pp.

  • Improvement: earnings conversion looks more confirmed, with CFO / net income at 1.09x.
  • Key risk: profitability remains under pressure, with trailing-12M net margin at 14.85% after a 2.8pp decline versus the same period last year.

Questions for the next period

  1. Whether revenue sustains its +29,0% YoY pace or begins to slow.

  2. Whether margins hold around the current 14.85% level or narrow again.

  3. Whether operating cash flow holds its 367.7bn (cumulative for 2025) level in upcoming periods or weakens.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio